LEIDEN, Netherlands, January 5, 2012 /PRNewswire/ -- Preclinical Study Provides Strong Rationale for HIV Vaccine Clinical Trials Results from a recent study

Netherlands-based biopharmaceutical company Crucell has received a National Institutes of Allergy and Infectious Diseases/National Institutes of Health contract aimed at advancing the development of a multivalent filovirus vaccine that includes both Ebola and Marburg viruses.

Crucell has reported that the novel recombinant adenovirus serotype 26 vector, which is jointly developed by Crucell and the Beth Israel Deaconess Medical Center, will be used in a Phase I clinical study to test a new HIV vaccine.

A phase 1 clinical trial to test a novel HIV/AIDS vaccine has begun at Brigham and Women’s Hospital (BWH). This new vaccine aims to overcome the problem of preexisting immunity to common vaccine vectors, which is thought to be a major problem in the developing world.

Recombinant adenovirus 26 vector avoids pre-existing immunity and is used in new HIV vaccine Leiden, The Netherlands, 3 April 2008 - Dutch biotechnology company Crucell N.V.